Table 1 Baseline demographics and clinical characteristics of the subjects (safety population)
Variables | Group 1 (n = 51) | Group 2 (n = 55) | Group 3 (n = 54) | p |
|---|---|---|---|---|
Age, years | 74.8 ± 8.2 | 75.0 ± 9.6 | 75.8 ± 8.2 | 0.867 |
Female, % | 60.8% | 60.0% | 63.0% | 0.958 |
Education, %low/med/high | 49/25.5/25.5 | 56.4/21.8/21.8 | 51.9/29.6/18.5 | 0.834 |
K-MMSE | 12.9 ± 5.3 | 13.7 ± 4.3 | 14.4 ± 4.7 | 0.247 |
CDR | 1.6 ± 0.6 | 1.7 ± 0.7 | 1.7 ± 0.5 | 0.877 |
GDS | 4.9 ± 0.6 | 4.8 ± 0.7 | 4.9 ± 0.7 | 0.679 |
Body weight, kg | 57.8 ± 8.7 | 59.2 ± 11.4 | 57.5 ± 9.9 | 0.628 |
BMI | 23.9 ± 2.7 | 24.1 ± 3.6 | 23.6 ± 3.1 | 0.752 |
Duration of donepezil, years | 1.8 ± 2.1 | 1.9 ± 2.0 | 2.0 ± 2.1 | 0.791 |
History of side effect d/t donepezil, % | 3.9% | 7.3% | 3.7% | 0.733 |
Hypertension, % | 43.1% | 58.2% | 40.7% | 0.147 |
DM, % | 19.6% | 27.3% | 25.9% | 0.661 |
Hyperlipidemia, % | 33.3% | 38.2% | 35.2% | 0.895 |
Brain injury, % | 7.8% | 7.3% | 9.3% | 0.937 |
Concomitant memantine | 16/51, 31.4% | 14/55, 25.5% | 14/54, 25.9% | 0.753 |